← Back to Conditions

Hyperphosphatemia

disorder
SNOMED 20165001CUI C0085681

Overview

Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Treatments & Interventions

Sevelamer

substance

Sevelamer hydrochloride

substance

Sevelamer carbonate

substance

Sucroferric oxyhydroxide

substance

Research Evidence

Peer-reviewed studies linked via MeSH term "Hyperphosphatemias" from the MEDLINE/PubMed database.

Sort:
Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients.
[object Object], [object Object], [object Object] et al. · Int Urol Nephrol · 2025
PMID: 39702842Meta-Analysis
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
[object Object], [object Object], [object Object] et al. · Cochrane Database Syst Rev · 2025
PMID: 40576086Meta-AnalysisFull text (PMC)
Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis.
[object Object], [object Object], [object Object] · Ren Fail · 2024
PMID: 39351794Meta-AnalysisFull text (PMC)
A Systematic Review of Online Resources for the Dietary Management of Hyperphosphatemia in People With Chronic Kidney Disease.
[object Object], [object Object], [object Object] et al. · J Ren Nutr · 2024
PMID: 38485068Meta-Analysis
Clinical Characteristics, Therapeutic Options, and Outcomes in Hyperphosphatemic Tumoral Calcinosis: A Systematic Review.
[object Object], [object Object], [object Object] et al. · Calcif Tissue Int · 2024
PMID: 38951179Meta-Analysis
Comparative Efficacy and Acceptability of 12 Phosphorus-Lowering Drugs in Adults with Hyperphosphatemia and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
[object Object], [object Object], [object Object] et al. · Blood Purif · 2023
PMID: 37591223Meta-Analysis
Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.
[object Object], [object Object], [object Object] · Ren Fail · 2023
PMID: 37272189Meta-AnalysisFull text (PMC)
Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
[object Object], [object Object], [object Object] et al. · Ther Apher Dial · 2023
PMID: 37349983Meta-Analysis
Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
[object Object], [object Object], [object Object] et al. · J Am Soc Nephrol · 2022
PMID: 34645696Meta-AnalysisFull text (PMC)
The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials.
[object Object], [object Object], [object Object] et al. · J Nephrol · 2022
PMID: 34061337Meta-Analysis
Search all PubMed articles for Hyperphosphatemia

Research data from MEDLINE/PubMed

Related Conditions

Raised calcium phosphate product(child)
Iatrogenic hyperphosphatemia(child)
Idiopathic hyperphosphatasemia(child)
Disorder of phosphorus metabolism(parent)

Quick Facts

SNOMED CT
20165001
UMLS CUI
C0085681
Fully Specified Name
Hyperphosphatemia (disorder)
Specialists
0
Diagnostic Biomarkers
0
Known Treatments
4
Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.